| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2023 ( Subtotal = $79,916,019 ) (Continued on the next page) |
| | 2023 | 2023 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01DK133885 | Extracellular Vesicle-mediated islet immune cross talk in Type 1 Diabetes pathogenesis | 000 | 2 | NIH | 4/28/2023 | $751,132 |
| | 2023 | 2023 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R21AI168750 | Use of a non-human primate model to define the role of T cell immune responses in persistent Kaposi sarcoma-associated herpesvirus infection and Kaposi sarcoma pathogenesis | 001 | 1 | NIH | 9/15/2023 | $345,516 |
| | 2023 | 2023 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA261793 | Leveraging Digital Health Solutions to Reduce Learning and Functional Disparities in Children with Cancer | 000 | 2 | NIH | 7/20/2023 | $774,388 |
| | 2023 | 2023 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA255250 | Identifying and engaging a universal adjuvant for breaking macrophage immune tolerance in cancer | 000 | 3 | NIH | 5/31/2023 | $422,872 |
| | 2023 | 2023 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01AG063854 | Defining the Role of Adipogenesis in Age-Associated Adiposity | 000 | 4 | NIH | 5/8/2023 | $360,800 |
| | 2023 | 2023 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA243386 | Targeting FTO to treat acute myeloid leukemia | 001 | 4 | NIH | 3/20/2023 | $45,603 |
| | 2023 | 2023 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | U01CA239373 | Optimizing GVHD Prevention with Systems Pharmacology Models | 001 | 5 | NIH | 7/25/2023 | $588,002 |
| | 2023 | 2023 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R21AI168750 | Use of a non-human primate model to define the role of T cell immune responses in persistent Kaposi sarcoma-associated herpesvirus infection and Kaposi sarcoma pathogenesis | 001 | 1 | NIH | 9/15/2023 | -$345,516 |
| | 2023 | 2023 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R21AI168750 | Use of a non-human primate model to define the role of T cell immune responses in persistent Kaposi sarcoma-associated herpesvirus infection and Kaposi sarcoma pathogenesis | 000 | 1 | NIH | 1/27/2023 | $345,516 |
| | 2023 | 2023 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R21CA277660 | Using Senolytics to Improve Physical Function in Older Breast Cancer Survivors | 001 | 1 | NIH | 9/1/2023 | -$139,694 |
| | 2023 | 2023 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R21CA270912 | Anti-CD25 Radioimmunotherapy and Total Marrow Irradiation for Treatment of Relapsed and Refractory Acute Leukemia | 000 | 2 | NIH | 2/17/2023 | $192,024 |
| | 2023 | 2023 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | OT3HL152932 | CureSC Manufacturing Resource Platform | 002 | 1 | NIH | 8/18/2023 | $1,785,617 |
| | 2023 | 2023 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | OT3HL152932 | CureSC Manufacturing Resource Platform | 001 | 1 | NIH | 4/17/2023 | $829,521 |
| | 2023 | 2023 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | OT3HL152932 | CureSC Manufacturing Resource Platform | 000 | 1 | NIH | 1/5/2023 | $473,533 |
| | 2023 | 2023 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01AG072291 | Develop age-relevant glial cellular models using human directly reprogrammed cells | 000 | 3 | NIH | 5/22/2023 | $440,000 |
| | 2023 | 2023 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA262754 | The role of CEACAM1 in oncogenic B-cell receptor signaling and immunotherapy in mantle cell lymphoma | 000 | 3 | NIH | 6/30/2023 | $393,530 |
| | 2023 | 2023 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA233664 | DNA repair gene mutations and prostate cancer | 000 | 4 | NIH | 1/31/2023 | $683,795 |
| | 2023 | 2023 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA266472 | Microbial- based targeting of major extracellular matrix components for improved therapy of pancreatic cancer | 000 | 2 | NIH | 8/28/2023 | $357,896 |
| | 2023 | 2023 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R21CA277660 | Using Senolytics to Improve Physical Function in Older Breast Cancer Survivors | 000 | 1 | NIH | 12/22/2022 | $205,700 |
| | 2023 | 2023 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R21CA270862 | Integrated Genotypic, Phenotypic and Immunologic Analysis of Ethnically Diverse Prostate Cancers | 000 | 2 | NIH | 3/1/2023 | $201,587 |
| | 2023 | 2023 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R50CA252135 | Improving Outcomes for Multiple Myeloma Patients through Novel Therapeutic Interventions | 000 | 3 | NIH | 8/29/2023 | $112,893 |
| | 2023 | 2023 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA256989 | Elucidating the role of DNAPKcs in chromosomal break end joining and clastogen resistance | 000 | 3 | NIH | 6/13/2023 | $394,548 |
| | 2023 | 2023 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R33AG059206 | Geriatric Oncology Research Infrastructure to Improve Clinical Care | 001 | 6 | NIH | 8/11/2023 | $669,573 |
| | 2023 | 2023 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA247550 | Characterizing and Targeting the Novel IL-15- AKT-XBP1s Pathway in NK Cells | 001 | 4 | NIH | 3/14/2023 | $35,654 |
| | 2023 | 2023 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA266783 | Transfer of vaccine-induced immunity from immunocompetent stem cell donor as antiviral immunotherapy to protect high-risk transplant recipients from cytomegalovirus reactivation | 000 | 1 | NIH | 5/2/2023 | $688,080 |
| | 2023 | 2023 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA263318 | Integration of epidemiology, pathology, immunology and outcomes in colorectal cancer | 001 | 2 | NIH | 8/23/2023 | $650,087 |
| | 2023 | 2023 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA266874 | A Phase 1 Study to Evaluate Chimeric Antigen Receptor (CAR) T cells Targeting TAG72 in Patients with Recurrent Epithelial Ovarian Cancer | 000 | 2 | NIH | 8/25/2023 | $689,955 |
| | 2023 | 2023 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R21CA267570 | Targeting MUC16 transactivation for ovarian cancer treatment | 001 | 2 | NIH | 3/22/2023 | $19,747 |
| | 2023 | 2023 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | U19CA264512 | Development of Small Molecule Inhibitors and Biologic Agents for Treatment of Glioblastoma Using Intracerebral Microdialysis and Signatures of Vulnerability | 002 | 3 | NIH | 9/12/2023 | $917,677 |
| | 2023 | 2023 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA241845 | Validation of epigenomic biomarkers for thyroid cancer diagnostics | 001 | 2 | NIH | 3/14/2023 | $67,259 |
| | 2023 | 2023 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | K08CA245193 | Impact of the Therapeutic Alliance on Reduction of Disparities in Latino End-of-Life Cancer Care | 000 | 5 | NIH | 6/7/2023 | $236,952 |
| | 2023 | 2023 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA247550 | Characterizing and Targeting the Novel IL-15- AKT-XBP1s Pathway in NK Cells | 000 | 4 | NIH | 11/8/2022 | $401,118 |
| | 2023 | 2023 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R56AG080294 | Circadian clock regulation of metabolic pathways in aging | 000 | 1 | NIH | 9/13/2023 | $440,000 |
| | 2023 | 2023 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | F99CA284248 | Defining the role of chromosomal break end synapsis factors for DNA repair | 000 | 1 | NIH | 8/15/2023 | $33,194 |
| | 2023 | 2023 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | F99CA274649 | Targeting a Novel Pocket on ITGAV | 001 | 2 | NIH | 9/13/2023 | $0 |
| | 2023 | 2023 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R21CA267570 | Targeting MUC16 transactivation for ovarian cancer treatment | 000 | 2 | NIH | 12/23/2022 | $222,156 |
| | 2023 | 2023 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA241845 | Validation of epigenomic biomarkers for thyroid cancer diagnostics | 000 | 2 | NIH | 11/18/2022 | $756,670 |
| | 2023 | 2023 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | U01CA250046 | Information flow and state transitions at the system and multi-dimensional scales in leukemia progression | 000 | 4 | NIH | 4/28/2023 | $700,616 |
| | 2023 | 2023 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | U01CA232216 | Experimental-Computational Synthesis of Altered Immune Signaling in Breast Cancer | 000 | 5 | NIH | 8/16/2023 | $183,872 |
| | 2023 | 2023 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | U01CA276195 | Identification of small molecule inhibitors to exonuclease 1 for breast cancer treatment | 000 | 1 | NIH | 8/2/2023 | $575,395 |
| | 2023 | 2023 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA278050 | Mechanism and therapeutic opportunities of targeting the Tudor domain | 000 | 1 | NIH | 11/28/2022 | $510,917 |
| | 2023 | 2023 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA269740 | Targeting the Microenvironment/Oncogene Cooperation to treat poor prognosis T-ALL | 000 | 1 | NIH | 3/9/2023 | $512,292 |
| | 2023 | 2023 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | F99CA274649 | Targeting a Novel Pocket on ITGAV | 000 | 2 | NIH | 8/21/2023 | $6,799 |
| | 2023 | 2023 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R21CA263223 | Modeling and Targeting B/Myeloid Mixed Phenotype Acute Leukemia | 000 | 2 | NIH | 1/31/2023 | $210,906 |
| | 2023 | 2023 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R21CA259932 | Genomic Analysis of Cutaneous CD30+ Lymphoproliferative Disorders | 000 | 2 | NIH | 2/15/2023 | $215,936 |
| | 2023 | 2023 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | U01NS122101 | A Human iPSC-based Cell Therapy for Canavan Disease | 001 | 3 | NIH | 6/23/2023 | $0 |
| | 2023 | 2023 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA249501 | Self-Management to Optimize Survivorship Care and Outcomes in Lung and Colorectal Cancer | 000 | 4 | NIH | 5/3/2023 | $801,402 |
| | 2023 | 2023 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA242218 | Precision approaches to refining TP53-associated cancer risk | 000 | 5 | NIH | 9/13/2023 | $1,709,326 |
| | 2023 | 2023 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010-3012 | LOS ANGELES | USA | R01CA284593 | Myeloid cell-selective, oligonucleotide-based STAT3 inhibition combined with total marrow and lymphoid irradiation for immunotherapy of acute myeloid leukemia | 000 | 1 | NIH | 7/19/2023 | $711,258 |
|
